-
Sector Analysis
NewEastern Europe Food Market Opportunities, Trends, Growth Analysis and Forecast to 2028
The global food industry was valued at $4.2 trillion in 2023 and is forecast to record a compound annual growth rate (CAGR) of 4.7%, reaching $5.2 trillion in 2028. Asia-Pacific was the largest region in terms of value and volume in 2023. Eastern Europe will register the fastest volume CAGR and the second-fastest value CAGR during 2023–28. Economies will recover from the adverse impact of the escalation of the Russia–Ukraine conflict and high inflation. Improved consumer confidence will help the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AAA-802 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AAA-802 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AAA-802 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CONV 01-alpha in Metastatic Castration-Resistant Prostate Cancer (mCRPC)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – [177Lu]Lu-rhPSMA-10.1 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - [177Lu]Lu-rhPSMA-10.1 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. [177Lu]Lu-rhPSMA-10.1 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lutetium-miltuximab in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lutetium-miltuximab in Metastatic Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lutetium-miltuximab in Metastatic Pancreatic Cancer Drug Details: Miltuximab is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lutetium-miltuximab in Metastatic Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lutetium-miltuximab in Metastatic Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lutetium-miltuximab in Metastatic Prostate Cancer Drug Details: Miltuximab is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lutetium-miltuximab in Bladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lutetium-miltuximab in Bladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lutetium-miltuximab in Bladder Cancer Drug Details: Miltuximab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lutetium-miltuximab in Urethral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lutetium-miltuximab in Urethral Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lutetium-miltuximab in Urethral Cancer Drug Details: Miltuximab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lutetium-miltuximab in Ureter Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lutetium-miltuximab in Ureter Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lutetium-miltuximab in Ureter Cancer Drug Details: Miltuximab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 177Lutetium-miltuximab in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 177Lutetium-miltuximab in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 177Lutetium-miltuximab in Metastatic Transitional (Urothelial) Tract Cancer Drug Details:...